Here's Why Keryx Biopharmaceuticals Fell 18% in October

Image source: Getty Images.

What happened

Shares of Keryx Biopharmaceuticals(NASDAQ: KERX), a commercial-stage company focused on renal disease, fell by 18% during the month of October, according to data fromS&P Global Market Intelligence.

KERX data by YCharts.

So what

Given the huge drop, you might assume that something bad happened to the company, but that doesn't appear to be the case. The only press release to come out of Keryx in October was to announce that it would be presenting data at the upcoming American Society of Nephrology Kidney Week in November.

Given the lack of news, it is likely that Keryx simply got caught up in the general biotech sell-off.

Here's a look at Keryx's monthly stock performance compared toSPDR S&P Biotech ETF (NYSEMKT: XBI).

KERX data by YCharts.

As you can see, the two roughly traded in tandem during October. In addition, it is worth remembering that shares of Keryx actuallyrose 28.6% in September.Against that backdrop, it is easy to understand why shares slumped.

Now what

Keryx is set to report its third-quarter results on Wednesday, Nov. 9. This will be a great chance forinvestors to learn how healthcare providers are responding to the company's manufacturing issues.

For what it is worth, analysts are expecting that the company's results will be rough. Current projections call roughly $5.3 million in total sales, which, if true, would represent a steep drop from the $9.3 million that was recorded in the second quarter.

Looking beyond the numbers, shareholders will want to listen in on the company's conference call to see if management still believes that the manufacturing issues will be completely resolved before year's end. Until we know more, the smart move is to remain cautious.

A secret billion-dollar stock opportunity The world's biggest tech company forgot to show you something, but a few Wall Street analysts and the Fool didn't miss a beat: There's a small company that's powering their brand-new gadgets and the coming revolution in technology. And we think its stock price has nearly unlimited room to run for early in-the-know investors! To be one of them, just click here.

Brian Feroldi has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.